Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

132
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
132
Cancer Survival Analysis01:21

Cancer Survival Analysis

343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respond to the commentary on "Government subsidy for infertility treatment: Impact on quality of life for infertile women undergoing in vitro fertilization-embryo transfer".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Context matters: coordinated transcriptional regulation and root plasticity under multinutrient conditions.

The New phytologist·2026
Same author

Sex-specific alterations of niacin flush pathway biomarkers in schizophrenia.

Psychoneuroendocrinology·2026
Same author

A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on Hemodialysis.

Journal of clinical pharmacology·2026
Same author

Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEM.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Male- and female-factor infertility and partners' quality of life during assisted reproductive technology: A dyadic actor-partner analysis.

Journal of the Chinese Medical Association : JCMA·2026

Related Experiment Video

Updated: Jun 25, 2025

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.1K

A novel Bayesian generative approach for estimating tumor dynamics from published studies.

Arya Pourzanjani1, Saurabh Modi1, Jamie Connarn1

  • 1Clinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.

CPT: Pharmacometrics & Systems Pharmacology
|May 23, 2024
PubMed
Summary

This study introduces a Bayesian model to estimate tumor growth inhibition (TGI) parameters from published summary data like progression-free survival (PFS) and objective response rate (ORR), overcoming limitations of sparse longitudinal tumor measurements.

More Related Videos

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
09:53

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography

Published on: August 16, 2020

7.2K
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
08:11

Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria

Published on: July 6, 2013

12.5K

Related Experiment Videos

Last Updated: Jun 25, 2025

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.1K
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
09:53

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography

Published on: August 16, 2020

7.2K
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
08:11

Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria

Published on: July 6, 2013

12.5K

Area of Science:

  • Pharmacometrics
  • Mathematical Oncology
  • Biostatistics

Background:

  • Tumor growth inhibition (TGI) models are valuable for understanding cancer therapy but require longitudinal tumor data, which is often unavailable.
  • Traditional exposure-response models rely on clinical endpoints, while TGI models offer a more dynamic view of tumor changes.
  • Published data commonly includes summary statistics such as progression-free survival (PFS) and objective response rate (ORR), derived from tumor measurements.

Purpose of the Study:

  • To develop a Bayesian generative model that estimates TGI model parameters using only summary-level PFS and ORR data.
  • To enable TGI modeling when detailed longitudinal tumor measurements are not accessible.
  • To provide a method for quantifying treatment effects and population variability in tumor dynamics.

Main Methods:

  • A Bayesian generative model was constructed to link underlying tumor dynamics with summary PFS and ORR data.
  • The model was fitted using publicly available summary data from multiple published cancer therapy studies.
  • Learned TGI model parameters were aggregated and used for in silico simulations.

Main Results:

  • The developed model successfully learned TGI parameters from summary data, demonstrating its feasibility.
  • The parameterized model effectively described tumor dynamics and quantified treatment effects.
  • The approach allowed for accounting for differences across various study populations.

Conclusions:

  • This novel Bayesian approach enables TGI modeling using readily available summary statistics (PFS, ORR), addressing data limitations.
  • The model facilitates a deeper understanding of tumor dynamics and treatment efficacy in oncology research.
  • The method's utility is validated through application to published studies and in silico trial simulation.